CORE-016: MICROSCOPY SHARED RESOURCE (MSR) PROJECT SUMMARY / ABSTRACT The Microscopy Shared Resource (MSR) is a strategically important research facility for OSUCCC members, providing transmission electron microscopy, scanning electron microscopy, two-photon confocal microscopy, confocal microscopy, widefield light microscopy, stereomicroscopy and live cell imaging. The MSR provides the expertise for microscopy consultation and training for investigators so that they can use the instruments 24 hours per day, 7 days a week, using key-card access. Alternatively, the MSR has available staff to assist investigators with more complex needs. Training and instruments also are available for sample preparation.
The Specific Aims are of the MSR are: 1) to provide a means for the OSUCCC research community to obtain publication quality, high-resolution images of their cancer research for use in manuscripts and grant applications; 2) to provide training to investigators for independent use of the instruments; and 3) to provide education and consultation opportunities to OSUCCC researchers for improved sample preparation and imaging. During the last grant period, the MSR provided approximately 14,263 hours of service to 116 OSUCCC program members representing all five OSUCCC research programs (Cancer Control, Leukemia Research, Molecular Biology and Cancer Genetics, Molecular Carcinogenesis and Chemoprevention, and Translational Therapeutics), contributed to 124 publications by OSUCCC members, including 9 with journal impact factors >10 and supported 60 awards, the vast majority of which were from the NCI (1 F31, 1 K12, 1 K24, 6 P01s, 2 P50s, 30 R01s, 14 R21s, 1 R37, 1 T32, and 3 U01s). Future plans for the MSR include new live cell imaging, super-resolution light microscopy and confocal capabilities. The MSR is supported by outstanding institutional resources obtained by leveraging extensive partnerships with the OSUCCC, OSU Colleges, the OSU Office of Research and grants from the State of Ohio, all totaling $1,768,341 over the prior grant period. As such, the MSR seeks only 11.2% budgetary support from CCSG funds. The Microscopy Shared Resource is part of the Diagnostics Grouping.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Rolfo, Christian; Mack, Philip C; Scagliotti, Giorgio V et al. (2018) Liquid Biopsy for Advanced Non-Small Cell LungĀ Cancer (NSCLC): A Statement Paper from theĀ IASLC. J Thorac Oncol 13:1248-1268
Ren, Yulin; Gallucci, Judith C; Li, Xinxin et al. (2018) Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens. J Nat Prod 81:554-561
McDonald, J Tyson; Kritharis, Athena; Beheshti, Afshin et al. (2018) Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. Oncotarget 9:22693-22702
Nguyen, Phuong; Wuthrick, Evan; Chablani, Priyanka et al. (2018) Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol 41:140-146
Elchuri, Sailaja V; Rajasekaran, Swetha; Miles, Wayne O (2018) RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development. Front Genet 9:170
Reiff, Sean D; Muhowski, Elizabeth M; Guinn, Daphne et al. (2018) Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood 132:1039-1049
Nabar, Gauri M; Mahajan, Kalpesh D; Calhoun, Mark A et al. (2018) Micelle-templated, poly(lactic-co-glycolic acid) nanoparticles for hydrophobic drug delivery. Int J Nanomedicine 13:351-366
Tang, Xiaowen; Yang, Lin; Li, Zheng et al. (2018) First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res 8:1083-1089
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539
Reeves, Katherine W; Pennell, Michael; Foraker, Randi E et al. (2018) Predictors of vasomotor symptoms among breast cancer survivors. J Cancer Surviv 12:379-387

Showing the most recent 10 out of 2602 publications